Article · Wikipedia archive · Last revised Jul 11, 2026

ASP-4345

ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia. It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia. The drug is taken orally.

Last revised
Jul 11, 2026
Read time
≈ 1 min
Length
330 w
Citations
23
Source
Wikipedia ↗
ASP-4345
Clinical data
Other namesASP4345
Routes of
administration		Oral123
Drug classDopamine D1 receptor positive allosteric modulator
ATC code
  • None
Pharmacokinetic data
Elimination half-life9.1–26.8 hours3
Identifiers
  • 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H14ClF3N4O3
Molar mass438.79 g·mol−1
3D model (JSmol)
  • CN(CC1=NC2=C(N1)C=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O
  • InChI=1S/C19H14ClF3N4O3/c1-26(8-16-24-12-4-2-10(19(21,22)23)6-13(12)25-16)17(28)9-27-14-7-11(20)3-5-15(14)30-18(27)29/h2-7H,8-9H2,1H3,(H,24,25)
  • Key:YJODOMNPYLHYJK-UHFFFAOYSA-N

ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.1453 It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia.1 The drug is taken orally.123

The most common side effects of ASP-4345 have been found to be headache and somnolence.2 No changes in mood or suicidality were observed.2 The pharmacokinetics of ASP-4345 have been studied.3 The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours.3 Its mean elimination half-life is 9.1 to 26.8 hours.3

ASP-4345 is or was under development by Astellas Pharma.14 As of March 2021, no recent development has been reported.1 The drug has reached phase 2 clinical trials for schizophrenia.14 It was found to be ineffective in a phase 2 trial.5

See also

See also

References

References

  1. "ASP 4345". AdisInsight. 9 March 2021. Retrieved 27 May 2026.
  2. Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, et al. (May 2021). "Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia". Neuropsychopharmacology. 46 (6): 1145–1151. doi:10.1038/s41386-020-00908-0. PMC 8182805. PMID 33203954.
  3. Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, et al. (January 2021). "Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies". Clinical Pharmacokinetics. 60 (1): 79–88. doi:10.1007/s40262-020-00911-0. PMC 7808976. PMID 32533536.
  4. "Delving into the Latest Updates on ASP-4345 with Synapse". Synapse. 15 November 2025. Retrieved 27 May 2026.
  5. Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI (September 2021). "Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments". International Journal of Molecular Sciences. 22 (18): 9905. doi:10.3390/ijms22189905. PMC 8468549. PMID 34576069.